Brandicourt reorganizes Sanofi
This article was originally published in Scrip
Sanofi's new CEO Olivier Brandicourt has wasted little time in stamping his mark on the French pharma giant. Bayer Healthcare's former chief, who took up the top job at Sanofi in April this year after the shock ousting of Christopher Viehbacher last October, has revealed plans to reorganize Sanofi's business operations with the creation of five global business units.
You may also be interested in...
Sanofi's CEO Olivier Brandicourt's reassuring 2017 guidance relies on continued cost savings, a successful launch of its Dupixent biologic, and winning a US legal case that threatens its PCSK9 inhibitor Praluent.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.